Peroxisome proliferator-activated receptor genetic polymorphisms and nonalcoholic fatty liver disease: Any role in disease susceptibility?

PPAR Research

Volumn , Issue , 2013, Pages

  Dongiovanni, Paola ^a   Valenti, Luca ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; INSULIN; LEUCINE; LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL; VALINE; VERY LOW DENSITY LIPOPROTEIN;

CARBOHYDRATE METABOLISM; DISEASE PREDISPOSITION; DYSLIPIDEMIA; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; ISCHEMIC HEART DISEASE; LIPID METABOLISM; LIVER BIOPSY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; OBESITY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TREATMENT RESPONSE;

EID: 84874633665     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2013/452061     Document Type: Review

References (71)

1. Marchesini G., Brizi M., Blanchi G., Tomassetti S., Bugianesi E., Lenzi M., McCullough A. J., Natale S., Forlani G., Melchionda N., Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001 50 8 1844 1850 2-s2.0-0035431018 (Pubitemid 33641605)
2. Kleiner D. E., Brunt E. M., Van Natta M., Behling C., Contos M. J., Cummings O. W., Ferrell L. D., Liu Y. C., Torbenson M. S., Unalp-Arida A., Yeh M., McCullough A. J., Sanyal A. J., Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005 41 6 1313 1321 2-s2.0-20044374023 10.1002/hep.20701 (Pubitemid 40770284)
3. Bugianesi E., Leone N., Vanni E., Marchesini G., Brunello F., Carucci P., Musso A., De Paolis P., Capussotti L., Salizzoni M., Rizzetto M., Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002 123 1 134 140 2-s2.0-0036302288 10.1053/gast.2002.34168 (Pubitemid 34747534)
4. Browning J. D., Szczepaniak L. S., Dobbins R., Nuremberg P., Horton J. D., Cohen J. C., Grundy S. M., Hobbs H. H., Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004 40 6 1387 1395 2-s2.0-10644220306 10.1002/hep.20466 (Pubitemid 39657013)
5. Bellentani S., Saccoccio G., Masutti F., Crocè L. S., Brandi G., Sasso F., Cristanini G., Tiribelli C., Prevalence of and risk factors for hepatic steatosis in northern Italy. Annals of Internal Medicine 2000 132 2 112 117 2-s2.0-0033982172 (Pubitemid 30044177)
6. Cohen J. C., Horton J. D., Hobbs H. H., Human fatty liver disease: old questions and new insights. Science 2011 332 6037 1519 1523 2-s2.0-79959517565 10.1126/science.1204265
7. Yamaguchi K., Yang L., McCall S., Huang J., Xing X. Y., Pandey S. K., Bhanot S., Monia B. P., Li Y. X., Diehl A. M., Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007 45 6 1366 1374 2-s2.0-34250356015 10.1002/hep.21655 (Pubitemid 46918320)
8. Donnelly K. L., Smith C. I., Schwarzenberg S. J., Jessurun J., Boldt M. D., Parks E. J., Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. Journal of Clinical Investigation 2005 115 5 1343 1351 2-s2.0-18244382304 10.1172/JCI200523621 (Pubitemid 40629054)
9. Bugianesi E., Gastaldelli A., Vanni E., Gambino R., Cassader M., Baldi S., Ponti V., Pagano G., Ferrannini E., Rizzetto M., Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005 48 4 634 642 2-s2.0-20944450486 10.1007/s00125-005-1682-x (Pubitemid 40591217)
10. Marchesini G., Brizi M., Morselli-Labate A. M., Bianchi G., Bugianesi E., McCullough A. J., Forlani G., Melchionda N., Association of nonalcoholic fatty liver disease with insulin resistance. American Journal of Medicine 1999 107 5 450 455 2-s2.0-0033231294 10.1016/S0002-9343(99)00271-5 (Pubitemid 29528333)
11. Korenblat K. M., Fabbrini E., Mohammed B. S., Klein S., Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 2008 134 5 1369 1375 2-s2.0-42949178538 10.1053/j.gastro.2008.01.075 (Pubitemid 351615354)
12. Targher G., Day C. P., Bonora E., Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. The New England Journal of Medicine 2010 363 14 1341 1350 2-s2.0-77957375969 10.1056/NEJMra0912063
13. Fabbrini E., Mohammed B. S., Magkos F., Korenblat K. M., Patterson B. W., Klein S., Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 2008 134 2 424 431 2-s2.0-38649111018 10.1053/j.gastro.2007.11.038 (Pubitemid 351173050)
14. Schwimmer J. B., Celedon M. A., Lavine J. E., Salem R., Campbell N., Schork N. J., Shiehmorteza M., Yokoo T., Chavez A., Middleton M. S., Sirlin C. B., Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009 136 5 1585 1592 2-s2.0-65249188812 10.1053/j.gastro.2009.01.050
15. Makkonen J., Pietiläinen K. H., Rissanen A., Kaprio J., Yki-Järvinen H., Genetic factors contribute to variation in serum alanine aminotransferase activity independent of obesity and alcohol: a study in monozygotic and dizygotic twins. Journal of Hepatology 2009 50 5 1035 1042 2-s2.0-64549098124 10.1016/j.jhep.2008.12.025
16. Guerrero R., Vega G. L., Grundy S. M., Browning J. D., Ethnic differences in hepatic steatosis: an insulin resistance paradox? Hepatology 2009 49 3 791 801 2-s2.0-63349086412 10.1002/hep.22726
17. Romeo S., Kozlitina J., Xing C., Pertsemlidis A., Cox D., Pennacchio L. A., Boerwinkle E., Cohen J. C., Hobbs H. H., Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nature Genetics 2008 40 12 1461 1465 2-s2.0-56749096610 10.1038/ng.257
18. Speliotes E. K., Yerges-Armstrong L. M., Wu J., Hernaez R., Kim L. J., Palmer C. D., Gudnason V., Eiriksdottir G., Garcia M. E., Launer L. J., Nalls M. A., Clark J. M., Mitchell B. D., Shuldiner A. R., Butler J. L., Tomas M., Hoffmann U., Hwang S. J., Massaro J. M., O'Donnell C. J., Sahani D. V., Salomaa V., Schadt E. E., Schwartz S. M., Siscovick D. S., Voight B. F., Carr J. J., Feitosa M. F., Harris T. B., Fox C. S., Smith A. V., Kao W. H. L., Hirschhorn J. N., Borecki I. B., Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genetics 2011 7 3 2-s2.0-79953745343 10.1371/journal. pgen.1001324 e1001324
19. Valenti L., Al-Serri A., Daly A. K., Enrico Galmozzi, Rametta R., Dongiovanni P., Nobili V., Mozzi E., Roviaro G., Vanni E., Bugianesi E., Maggioni M., LudovicaFracanzani A., Fargion S., Day C. P., Homozygosity for the patatin-like phospholipase-3/adiponutrin i148m polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010 51 4 1209 1217 2-s2.0-77950607738 10.1002/hep.23622
20. Sookoian S., Pirola C. J., Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011 53 6 1883 1894 2-s2.0-79957462315 10.1002/hep.24283
21. Dongiovanni P., Valenti L., Rametta R., Daly A. K., Nobili V., Mozzi E., Leathart J. B. S., Pietrobattista A., Burt A. D., Maggioni M., Fracanzani A. L., Lattuada E., Zappa M. A., Roviaro G., Marchesini G., Day C. P., Fargion S., Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut 2010 59 2 267 273 2-s2.0-77149168465 10.1136/gut.2009.190801
22. Al-Serri A., Anstee Q. M., Valenti L., Nobili V., Leathart J. B., Dongiovanni P., Patch J., Fracanzani A., Fargion S., Day C. P., Daly A. K., The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. Journal of Hepatology 2012 56 2 448 454 10.1016/j.jhep.2011.05.029
23. Miele L., Beale G., Patman G., Nobili V., Leathart J., Grieco A., Abate M., Friedman S. L., Narla G., Bugianesi E., Day C. P., Reeves H. L., The Kruppel-Like Factor 6 Genotype Is Associated With Fibrosis in Nonalcoholic Fatty Liver Disease. Gastroenterology 2008 135 1 282 291 2-s2.0-46049097550 10.1053/j.gastro.2008.04.004 (Pubitemid 351899026)
24. Chen S., Li Y., Li S., Yu C., A Val227Ala substitution in the peroxisome proliferator activated receptor alpha (PPAR alpha) gene associated with non-alcoholic fatty liver disease and decreased waist circumference and waist-to-hip ratio. Journal of Gastroenterology and Hepatology 2008 23 9 1415 1418 2-s2.0-49849093922 10.1111/j.1440-1746.2008.05523.x
25. Dongiovanni P., Rametta R., Fracanzani A. L., Benedan L., Borroni V., Maggioni P., Maggioni M., Fargion S., Valenti L., Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study. BMC Gastroenterology 2010 10, article 102 2-s2.0-77956461321 10.1186/1471-230X-10-102
26. Shulman A. I., Mangelsdorf D. J., Retinoid X receptor heterodimers in the metabolic syndrome. The New England Journal of Medicine 2005 353 6 604 615 2-s2.0-23444431623 10.1056/NEJMra043590 (Pubitemid 41138942)
27. Bensinger S. J., Tontonoz P., Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008 454 7203 470 477 2-s2.0-47949094965 10.1038/nature07202
28. Kliewer S. A., Forman B. M., Blumberg B., Ong E. S., Borgmeyer U., Mangelsdorf D. J., Umesono K., Evans R. M., Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proceedings of the National Academy of Sciences of the United States of America 1994 91 15 7355 7359 2-s2.0-0028321529 10.1073/pnas.91.15.7355 (Pubitemid 24226862)
29. Leone T. C., Weinheimer C. J., Kelly D. P., A critical role for the peroxisome proliferator-activated receptor (PPAR) in the cellular fasting response: the PPAR null mouse as a model of fatty acid oxidation disorders. Proceedings of the National Academy of Sciences of the United States of America 1999 96 13 7473 7478 2-s2.0-0033594980 10.1073/pnas.96.13.7473 (Pubitemid 29299686)
30. Kersten S., Seydoux J., Peters J. M., Gonzalez F. J., Desvergne B., Wahli W., Peroxisome proliferator-activated receptor mediates the adaptive response to fasting. Journal of Clinical Investigation 1999 103 11 1489 1498 2-s2.0-0032699670
31. Stienstra R., Saudale F., Duval C., Keshtkar S., Groener J. E. M., Van Rooijen N., Staels B., Kersten S., Müller M., Kupffer cells promote hepatic steatosis via interleukin-1 β -dependent suppression of peroxisome proliferator-activated receptor activity. Hepatology 2010 51 2 511 522 2-s2.0-75449101395 10.1002/hep.23337
32. Yamakawa-Kobayashi K., Ishiguro H., Arinami T., Miyazaki R., Hamaguchi H., A Val227 ala polymorphism in the peroxisome proliferator activated receptor (PPAR) gene is associated with variations in serum lipid levels [2]. Journal of Medical Genetics 2002 39 3 189 191 2-s2.0-0036009175 (Pubitemid 34252556)
33. Sparsø T., Hussain M. S., Andersen G., Hainerova I., Borch-Johnsen K., Jørgensen T., Hansen T., Pedersen O., Relationships between the functional PPAR Leu162Val polymorphism and obesity, type 2 diabetes, dyslipidaemia, and related quantitative traits in studies of 5799 middle-aged white people. Molecular Genetics and Metabolism 2007 90 2 205 209 2-s2.0-33846382723 10.1016/j.ymgme.2006.10.007 (Pubitemid 46127654)
34. Beaven S. W., Tontonoz P., Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. Annual Review of Medicine 2006 57 313 329 2-s2.0-32944473282 10.1146/annurev.med.57.121304.131428 (Pubitemid 43261994)
35. Wu Z., Rosen E. D., Brun R., Hauser S., Adelmant G., Troy A. E., McKeon C., Darlington G. J., Spiegelman B. M., Cross-regulation of C/EBP and PPAR γ controls the transcriptional pathway of adipogenesis and insulin sensitivity. Molecular Cell 1999 3 2 151 158 2-s2.0-0033083803 10.1016/S1097-2765(00)80306-8 (Pubitemid 29292616)
36. He W., Barak Y., Hevener A., Olson P., Liao D., Le J., Nelson M., Ong E., Olefsky J. M., Evans R. M., Adipose-specific peroxisome proliferator-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscle. Proceedings of the National Academy of Sciences of the United States of America 2003 100 26 15712 15717 2-s2.0-9144229185 10.1073/pnas.2536828100 (Pubitemid 38021055)
37. Kadowaki T., Yamauchi T., Adiponectin and adiponectin receptors. Endocrine Reviews 2005 26 3 439 451 2-s2.0-18844432308 10.1210/er.2005-0005 (Pubitemid 40686653)
38. Wu Z., Xie Y., Morrison R. F., Bucher N. L. R., Farmer S. R., PPAR γ induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBP during the conversion of 3T3 fibroblasts into adipocytes. Journal of Clinical Investigation 1998 101 1 22 32 2-s2.0-0031595111 (Pubitemid 28058899)
39. Belfort R., Harrison S. A., Brown K., Darland C., Finch J., Hardies J., Balas B., Gastaldelli A., Tio F., Pulcini J., Berria R., Ma J. Z., Dwivedi S., Havranek R., Fincke C., DeFronzo R., Bannayan G. A., Schenker S., Cusi K., A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England Journal of Medicine 2006 355 22 2297 2307 2-s2.0-33751545838 10.1056/NEJMoa060326 (Pubitemid 44837778)
40. Gastaldelli A., Harrison S. A., Belfort-Aguilar R., Hardies L. J., Balas B., Schenker S., Cusi K., Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 2009 50 4 1087 1093 2-s2.0-70350064027 10.1002/hep.23116
41. Jiang G., Dallas-Yang Q., Li Z., Szalkowski D., Liu F., Shen X., Wu M., Zhou G., Doebber T., Berger J., Moller D. E., Zhang B. B., Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPAR γ agonists. Diabetes 2002 51 8 2412 2419 2-s2.0-0036326005 (Pubitemid 34827389)
42. Gerhold D. L., Franklin L. I. U., Jiang G., Zhihua L. I., Jian X. U., Meiqing L. U., Sachs J. R., Bagchi A., Fridman A., Holder D. J., Doebber T. W., Berger J., Elbrecht A., Moller D. E., Zhang B. B., Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator- activated receptor- γ agonists. Endocrinology 2002 143 6 2106 2118 2-s2.0-18344390234 10.1210/en.143.6.2106 (Pubitemid 34521558)
43. Gurnell M., Savage D. B., Chatterjee V. K. K., O'Rahilly S., The metabolic syndrome: peroxisome proliferator-activated receptor γ and its therapeutic modulation. Journal of Clinical Endocrinology and Metabolism 2003 88 6 2412 2421 2-s2.0-0038645828 (Pubitemid 36724405)
44. Barroso I., Gurnell M., Crowley V. E. F., Agostini M., Schwabe J. W., Soos M. A., Maslen G. L., Williams T. D. M., Lewis H., Schafer A. J., Chatterjee V. K. K., O'Rahilly S., Dominant negative mutations in human PPAR γ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999 402 6764 880 883 2-s2.0-0033599038 10.1038/47254 (Pubitemid 30017170)
45. Altshuler D., Hirschhorn J. N., Klannemark M., Lindgren C. M., Vohl M. C., Nemesh J., Lane C. R., Schaffner S. F., Bolk S., Brewer C., Tuomi T., Gaudet D., Hudson T. J., Daly M., Groop L., Lander E. S., The common PPAR γ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nature Genetics 2000 26 1 76 80 2-s2.0-0033624575 10.1038/79216
46. Zhu Y., Qi C., Korenberg J. R., Chen X. N., Noya D., Sambasiva Rao M., Reddy J. K., Structural organization of mouse peroxisome proliferator-activated receptor γ (mPPAR γ) gene: alternative promoter use and different splicing yield two mPPAR γ isoforms. Proceedings of the National Academy of Sciences of the United States of America 1995 92 17 7921 7925 2-s2.0-0029102676 10.1073/pnas.92.17.7921
47. Knouff C., Auwerx J., Peroxisome proliferator-activated receptor- γ calls for activation in moderation: lessons from genetics and pharmacology. Endocrine Reviews 2004 25 6 899 918 2-s2.0-10644251916 10.1210/er.2003-0036 (Pubitemid 39657772)
48. Tankó L. B., Siddiq A., Lecoeur C., Larsen P. J., Christiansen C., Walley A., Froguel P., ACDC/adiponectin and PPAR- γ gene polymorphisms: implications for features of obesity. Obesity Research 2005 13 12 2113 2121 2-s2.0-33645062714
49. Tönjes A., Stumvoll M., The role of the Pro12Ala polymorphism in peroxisome proliferator-activated receptor γ in diabetes risk. Current Opinion in Clinical Nutrition and Metabolic Care 2007 10 4 410 414 2-s2.0-34250674020 10.1097/MCO.0b013e3281e389d9 (Pubitemid 46934108)
50. He W., PPAR γPro12Ala polymorphism and human health. PPAR Research 2009 2009 15 849538 10.1155/2009/849538
51. Gawrieh S., Marion M. C., Komorowski R., Wallace J., Charlton M., Kissebah A., Langefeld C. D., Olivier M., Genetic variation in the peroxisome proliferator activated receptor-gamma gene is associated with histologically advanced NAFLD. Digestive Diseases and Sciences 2011 57 4 952 957 10.1007/s10620-011-1994-2
52. Gupta A. C., Chaudhory A. K., Sukriti, Pande C., Sakhuja P., Singh Y., Basir S. F., Sarin S. K., Peroxisome proliferators-activated receptor γ 2 Pro12Ala variant is associated with body mass index in non-alcoholic fatty liver disease patients. Hepatology International 2011 5 1 575 580 2-s2.0-79952631265 10.1007/s12072-010-9225-z
53. Rey J. W., Noetel A., Hardt A., Canbay A., Alakus H., zur Hausen A., Dienes H. P., Drebber U., Odenthal M., Pro12Ala polymorphism of the peroxisome proliferatoractivated receptor γ 2 in patients with fatty liver diseases. World Journal of Gastroenterology 2010 16 46 5830 5837 2-s2.0-78650592847 10.3748/wjg.v16.i46.5830
54. Yang Z., Wen J., Li Q., Tao X., Ye Z., He M., Zhang W., Huang Y., Chen L., Ling C., Qu S., Hu R., PPARG gene Pro12Ala variant contributes to the development of non-alcoholic fatty liver in middle-aged and older Chinese population. Molecular and Cellular Endocrinology 348 1 255 259 10.1016/j.mce.2011.09.001
55. Thamer C., Machann J., Tschritter O., Haap M., Wietek B., Dahl D., Bachmann O., Fritsche A., Jacob S., Stumvoll M., Schick F., Häring H. U., Relationship between serum adiponectin concentration and intramyocellular lipid stores in humans. Hormone and Metabolic Research 2002 34 11-12 646 649 2-s2.0-0036875149 10.1055/s-2002-38260 (Pubitemid 36398700)
56. Zhou Y. J., Li Y. Y., Nie Y. Q., Yang H., Zhan Q., Huang J., Shi S. L., Lai X. B., Huang H. L., Influence of polygenetic polymorphisms on the susceptibility to non-alcoholic fatty liver disease of Chinese people. Journal of Gastroenterology and Hepatology 2010 25 4 772 777 2-s2.0-77950158252 10.1111/j.1440-1746.2009.06144.x
57. Bhatt S. P., Nigam P., Misra A., Guleria R., Luthra K., Pandey R. M., Pasha M. A., Association of peroxisome proliferator activated receptor- γ gene with non-alcoholic fatty liver disease in Asian Indians residing in north India. Gene 2013 512 1 143 147 10.1016/j.gene.2012.09.067
58. Schulman I. G., Nuclear receptors as drug targets for metabolic disease. Advanced Drug Delivery Reviews 2010 62 13 1307 1315 2-s2.0-78649325832 10.1016/j.addr.2010.07.002
59. Chawla A., Lee C. H., Barak Y., He W., Rosenfeld J., Liao D., Han J., Kang H., Evans R. M., PPAR δ is a very low-density lipoprotein sensor in macrophages. Proceedings of the National Academy of Sciences of the United States of America 2003 100 3 1268 1273 2-s2.0-0037417726 10.1073/pnas.0337331100 (Pubitemid 36183991)
60. Lee C. H., Kang K., Mehl I. R., Nofsinger R., Alaynick W. A., Chong L. W., Rosenfeld J. M., Evans R. M., Peroxisome proliferator-activated receptor δ promotes very low-density lipoprotein-derived fatty acid catabolism in the macrophage. Proceedings of the National Academy of Sciences of the United States of America 2006 103 7 2434 2439 2-s2.0-33144455156 10.1073/pnas. 0510815103 (Pubitemid 43271687)
61. Barak Y., Liao D., He W., Ong E. S., Nelson M. C., Olefsky J. M., Boland R., Evans R. M., Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America 2002 99 1 303 308 2-s2.0-0037039374 10.1073/pnas.012610299 (Pubitemid 34060358)
62. Barish G. D., Narkar V. A., Evans R. M., PPAR δ: a dagger in the heart of the metabolic syndrome. Journal of Clinical Investigation 2006 116 3 590 597 2-s2.0-33644645013 10.1172/JCI27955 (Pubitemid 43326863)
63. Fürnsinn C., Willson T. M., Brunmair B., Peroxisome proliferator-activated receptor- δ a regulator of oxidative capacity, fuel switching and cholesterol transport. Diabetologia 2007 50 1 8 17 2-s2.0-33845940226 10.1007/s00125-006-0492-0 (Pubitemid 46035846)
64. Billin A. N., PPAR- β / δ agonists for type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home. Expert Opinion on Investigational Drugs 2008 17 10 1465 1471 2-s2.0-52949099182 10.1517/13543784.17.10.1465
65. Skogsberg J., Kannisto K., Roshani L., Gagne E., Hamsten A., Larsson C., Ehrenborg E., Characterization of the human peroxisome proliferator activated receptor delta gene and its expression. International Journal of Molecular Medicine 2000 6 1 73 81 2-s2.0-0034220890
66. Skogsberg J., Kannisto K., Cassel T. N., Hamsten A., Eriksson P., Ehrenborg E., Evidence that peroxisome proliferator-activated receptor delta influences cholesterol metabolism in men. Arteriosclerosis, Thrombosis, and Vascular Biology 2003 23 4 637 643 2-s2.0-0037387593 10.1161/01.ATV.0000064383. 88696.24 (Pubitemid 36438077)
67. Skogsberg J., McMahon A. D., Karpe F., Hamsten A., Packard C. J., Ehrenborg E., Peroxisome proliferator activated receptor delta genotype in relation to cardiovascular risk factors and risk of coronary heart disease in hypercholesterolaemic men. Journal of Internal Medicine 2003 254 6 597 604 2-s2.0-0348134971 10.1111/j.1365-2796.2003.01236.x (Pubitemid 37521857)
68. Aberle J., Hopfer I., Beil F. U., Seedorf U., Association of the T+294C polymorphism in PPAR δ with low HDL cholesterol and coronary heart disease risk in women. International Journal of Medical Sciences 2006 3 3 108 111 2-s2.0-33745819570 (Pubitemid 44035233)
69. Robitaille J., Gaudet D., Pérusse L., Vohl M. C., Features of the metabolic syndrome are modulated by an interaction between the peroxisome proliferator-activated receptor-delta -87T>C polymorphism and dietary fat in French-Canadians. International Journal of Obesity 2007 31 3 411 417 2-s2.0-33847256899 10.1038/sj.ijo.0803450
70. Andrulionyte L., Peltola P., Chiasson J. L., Laakso M., Single nucleotide polymorphisms of PPARD in combination with the Gly482Ser substitution of PGC-1A and the Pro12Ala substitution of PPARG2 predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. Diabetes 2006 55 7 2148 2152 2-s2.0-33747060509 10.2337/db05-1629 (Pubitemid 44509991)
71. Grarup N., Albrechtsen A., Ek J., Borch-Johnsen K., Jørgensen T., Schmitz O., Hansen T., Pedersen O., Variation in the peroxisome proliferator-activated receptor δ gene in relation to common metabolic traits in 7,495 middle-aged white people. Diabetologia 2007 50 6 1201 1208 2-s2.0-34247844401 10.1007/s00125-007-0668-2 (Pubitemid 46701567)